Home > Neurology > Ocrelizumab benefits maintained in primary progressive MS

Ocrelizumab benefits maintained in primary progressive MS

Lancet Neurology
Reuters Health - 05/11/2020 - Primary progressive multiple sclerosis (MS) patients treated with ocrelizumab show sustained long-term benefit, a post-hoc analysis of the phase-3 ORATORIO trial's open-label extension period shows. Those initially randomized to ocrelizumab had less disease progression based on disability measures and imaging studies than those who started the study on placebo, Dr. Jerry S. Wolinsky of McGovern Medical School at The University of Texas Health Science Center at Houston and colleagues found. "To me the beauty of this study was at the same time the drug ocrelizumab was being tried in classic relapsing-remitting disease, we were doing this study in primary progressive disease, so that we could have enough common elements in those studies as to begin to understand how similar or how different relapsing and primary progressive disease really are," Dr. Wolinsky noted. "The benefits that we're seeing were maintained in the group that was...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on